Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease
Abstract
In this modern era, with the help of various advanced technologies, medical science has overcome most of the health-related issues successfully. Though, some diseases still remain unresolved due to various physiological barriers. One such condition is Alzheimer; a neurodegenerative disorder characterized by progressive memory impairment, behavioral abnormalities, mood swing and disturbed routine activities of the person suffering from. It is well known to all that the brain is entirely covered by a protective layer commonly known as blood brain barrier (BBB) which is responsible to maintain the homeostasis of brain by restricting the entry of toxic substances, drug molecules, various proteins and peptides, small hydrophilic molecules, large lipophilic substances and so many other peripheral components to protect the brain from any harmful stimuli. This functionally essential structure creates a major hurdle for delivery of any drug into the brain. Still, there are some provisions on BBB which facilitate the entry of useful substances in the brain via specific mechanisms like passive diffusion, receptor-mediated transcytosis, carrier-mediated transcytosis etc. Another important factor for drug transport is the selection of a suitable drug delivery systems like, liposome, which is a novel drug carrier system offering a potential approach to resolving this problem. Its unique phospholipid bilayer structure (similar to physiological membrane) had made it more compatible with the lipoidal layer of BBB and helps the drug to enter the brain. The present review work focused on various surface modifications with functional ligand (like lactoferrin, transferrin etc.) and carrier molecules (such as glutathione, glucose etc.) on the liposomal structure to enhance its brain targeting ability towards the successful treatment of Alzheimer disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanoliposomes and exosomes are promising smart drug delivery systems able to penetrate the blood-brain barrier and target brain tissues.
“Studies show the promising role of nanoliposomes and exosomes as smart drug delivery systems able to penetrate the blood–brain barrier and target brain tissues.”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [32]
Soft nanoparticles such as nanoliposomes or exosomes represent one of the most effective drug delivery processes to protect therapeutic agents and deliver them to target tissues.
“Soft NP, such as nanoliposomes (NL) or exosomes, represent one of the most effective drug delivery processes to be able to protect therapeutic agents and deliver them to the target tissues [32,33].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [32]
Binding to serum proteins and nonspecific uptake of cationic liposomes by peripheral tissues are major drawbacks that require administration of highly toxic doses to achieve therapeutic efficacy.
“However, binding to serum proteins and the nonspecific uptake of cationic liposomes by peripheral tissues are major drawbacks that require the administration of highly toxic doses of liposomes to achieve therapeutic efficacy [32].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [32]
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · see citing works
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works
Detering, K. M., Hancock, A. D., Reade, M. C., & Silvester, W. (2010) · BMJ · doi:10.1136/bmj.c1345 · Cited by 2,332 · see citing works
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works
Hippocampal neurons in pre-clinical Alzheimer's disease.
West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., & Troncoso, J. C. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.005 · Cited by 317 · cited 1× · see citing works
“These fragments have a tendency to normally get dissolved and eliminated from the brain but in elderly peoples or person with some abnormalities, this peptide gets accumulated and forms a large aggregate that causes nerve degeneration and may lead to Alzheimer disease [15].”
BackgroundNerve growth factor promotes survival of new neurons in the adult hippocampus
Frielingsdorf, H., Simpson, D. R., Thal, L. J., & Pizzo, D. P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.015 · Cited by 151 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s264498 · Cited by 1,323 · see citing works
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651 · see citing works
Vatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., Barthakur, S., Kasendra, M., Lucchesi, C., Kerns, J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.011 · Cited by 632 · see citing works
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · see citing works
Self-citationAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 592 · see citing works
“Soft NP, such as nanoliposomes (NL) or exosomes, represent one of the most effective drug delivery processes to be able to protect therapeutic agents and deliver them to the target tissues [32,33].”
BackgroundMethodInfluentialXiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232 · see citing works
Lipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187 · see citing works
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129 · see citing works
Liu, Y., Gong, Y., Xie, W., Huang, A., Yuan, X., Zhou, H., Zhu, X., Chen, X., Liu, J., Liu, J., et al. (2020) · Nanoscale · doi:10.1039/c9nr09713a · Cited by 123 · see citing works
New hope for Parkinson’s disease treatment: Targeting gut microbiota
Fan, H., Sheng, S., & Zhang, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13916 · Cited by 66 · see citing works
Haddad, M., Hervé, V., Ben Khedher, M. R., Rabanel, J.-M., & Ramassamy, C. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8129 · Cited by 68 · see citing works
Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment
Luiz, M. T., Viegas, J. S. R., Abriata, J. P., Tofani, L. B., Vaidergorn, M. D. M., Emery, F. D. S., Chorilli, M., & Marchetti, J. M. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2021.112033 · Cited by 62 · see citing works
Fu, C., Xiang, Y., Li, X., & Fu, A. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.029 · Cited by 48 · see citing works
Ligand conjugation: An emerging platform for enhanced brain drug delivery
Nabi, B., Rehman, S., Khan, S., Baboota, S., & Ali, J. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.08.003 · Cited by 44 · see citing works
- Authors
- Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A.
- Affiliations
- Rungta College (IN)
- Pandit Ravishankar Shukla University (IN)
- University of Patras (GR)
- Corresponding author
- Alexander, Amit
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 260
- Pages
- 61-77
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2617943552
- Cited by
- 356
- References
- 6
- Citations by year
- 2026: 18 · 2025: 42 · 2024: 46 · 2023: 44 · 2022: 58 · 2021: 43 · 2020: 52 · 2019: 26 · 2018: 23 · 2017: 3
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Science and Technology (SR/FST/LSI-434/2010)
- UGC-SAP (3-54/2011)
- Science and Engineering Research Board (YSS/2015/001751)
- Chhattisgarh Council of Science and Technology (1124/CCOST/MRP/2015, 1115/CCOST/MRP/2015)
- University Grant Commission (MRP ID: MRP-MAJOR-PHAR-2013-31484)
- All India Council for Technical Education (8-126/RIFD/Policy-3/2013-14)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- liposomes, blood-brain barrier, Alzheimer's disease, brain drug delivery, surface modification, active targeting, lactoferrin, transferrin, glutathione, glucose, receptor-mediated transcytosis, phospholipid bilayers
- MeSH terms
- Administration, Intranasal, Alzheimer Disease, Animals, Blood-Brain Barrier, Humans, Liposomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
